Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Prostatic Neoplasms 67Neoplasm Metastasis 6Prostatic Neoplasms, Castration-Resistant 4Metastatic Castration-resistant Prostate Cancer 4Neoplasms 3Prostate Cancer Metastatic 2Metastatic Castration Resistant Prostate Cancer 2Breast Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Newly Diagnosed Oligometastatic Prostate Cancer 1Metastatic Castration-sensitive Prostate Cancer 1Hyperaldosteronism 1Castration-resistant Prostate Cancer 1Castrate-resistant Prostate Cancer 1Adenocarcinoma 1

Interventions

Trastuzumab 243Paclitaxel 193Cyclophosphamide 158Docetaxel 134Letrozole 113Capecitabine 113Fulvestrant 106Doxorubicin 103Bevacizumab 87Carboplatin 81exemestane 80Anastrozole 79Lapatinib 70Tamoxifen 69Albumin-Bound Paclitaxel 57palbociclib 54pertuzumab 53Taxes 51Gemcitabine 50Radiotherapy 46eribulin 43pembrolizumab 41Everolimus 41Ado-Trastuzumab Emtansine 41Vinorelbine 38130-nm albumin-bound paclitaxel 35ixabepilone 32Epirubicin 28pegfilgrastim 25liposomal doxorubicin 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Breast Neoplasms × Abiraterone Acetate × Clear all
NCT01517802 2022-05-10

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Janssen Research & Development, LLC

Phase 3 Completed
32 enrolled 7 charts
Breast

Breast Neoplasms

NCT01381874 2019-04-11

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Janssen Research & Development, LLC

Phase 2 Completed
297 enrolled 19 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡